Department of Radiology, University of Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany.
Department of Nuclear Medicine, University of Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany.
Eur Radiol. 2016 Aug;26(8):2779-89. doi: 10.1007/s00330-015-4076-6. Epub 2015 Nov 11.
To retrospectively determine incidence of early arterial blood flow stasis and its influencing factors during resin-based radioembolization (RE) of liver tumours.
Data of patients undergoing resin-based RE from 06/2006-12/2013 were reviewed. Second RE procedures of the same liver lobe were excluded. 90-yttrium dose was calculated according to the body surface area method. Data were categorized according to RE without full dose application because of early stasis and with full dose application. Clinical/procedural characteristics were recorded. Logistic regression was performed to identify associations between clinical/procedural characteristics and early stasis.
362 patients [220 male; mean age 62 years (range 26-90)] underwent 416 RE sessions with early stasis occurring in 103 REs (24.8 %). Highest incidence and degree of stasis were observed in breast cancer metastases [42.6 % (20/47); 55.8 % of mean intended dose administered]. Independent risk factors were: metastasized breast cancer (odds ratio [OR] 2.18, p = 0.02), liver tumour-burden <25 % and 25-50 % (ORs 5.33, 15.64; p < 0.0001), tumour hypovascularity (OR 2.70, p = 0.04), previous bevacizumab therapy (OR 2.79, p = 0.0009) and concurrent chemotherapy (OR 8.69, p < 0.0001).
Early stasis was observed in 24.8 % of resin-based REs. In the presence of the identified risk factors, extra care should be taken during microsphere administration.
• Early arterial blood flow stasis is a known problem of resin-based RE. • The study showed that early stasis occurs in 25 % of REs. • Several clinical and procedural factors are associated with early stasis. • In patients at risk extra care should be taken during RE.
回顾性分析树脂基放射性栓塞(RE)治疗肝肿瘤时早期动脉血流淤滞的发生率及其影响因素。
回顾性分析 2006 年 6 月至 2013 年 12 月期间行树脂基 RE 的患者资料。排除同一肝叶的二次 RE 治疗。90 钇剂量按体表面积法计算。根据是否因早期淤滞而未全剂量应用及全剂量应用将数据分类。记录临床/手术特点。采用 Logistic 回归分析临床/手术特点与早期淤滞的关系。
362 例患者(220 例男性;平均年龄 62 岁[范围 26-90 岁])共行 416 次 RE 治疗,其中 103 次(24.8%)出现早期淤滞。乳腺癌转移患者的淤滞发生率和程度最高[42.6%(20/47);平均给予的目标剂量的 55.8%]。独立的危险因素为:转移性乳腺癌(比值比[OR] 2.18,p=0.02)、肝肿瘤负荷<25%和 25-50%(ORs 5.33,15.64;p<0.0001)、肿瘤乏血供(OR 2.70,p=0.04)、贝伐单抗治疗史(OR 2.79,p=0.0009)和同期化疗(OR 8.69,p<0.0001)。
在树脂基 RE 中,早期淤滞的发生率为 24.8%。存在上述确定的危险因素时,在微球给药期间应格外小心。
早期动脉血流淤滞是树脂基 RE 的已知问题。
本研究显示,早期淤滞发生在 25%的 RE 中。
几种临床和手术因素与早期淤滞相关。
高危患者在进行 RE 时应格外小心。